Ophthalmology · Camillus, NY
NPI
1831166545
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
5700 W Genesee St, Suite 112
Camillus, NY, 13031
Phone (315) 488-1601
Groups this clinician bills Medicare through
Medicare paid, 2024
$124K
2,499 services
Medicare patients, 2024
569
Average age 72
Drug cost, 2024
$751K
7,317 prescriptions
Company payments, 2023
$40.71
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Samuel G Alpert was code 92134 (computerized ophthalmic imaging), 539 times for 296 patients. In total Samuel G Alpert billed 2,499 services in 61 codes, and Medicare paid $124K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-04-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92134 Computerized Ophthalmic Imaging | Facility | 539 | 296 | $17.05 | $9,192 |
| 99214 Office E&M - Established | Facility | 364 | 246 | $62.02 | $23K |
| 92083 Vision, Hearing, and Speech Services | Facility | 357 | 222 | $17.86 | $6,376 |
| 99213 Office E&M - Established | Facility | 303 | 195 | $44.56 | $14K |
| 92133 Computerized Ophthalmic Imaging | Facility | 153 | 132 | $13.67 | $2,091 |
| 92020 Ophthalmological E&M | Facility | 108 | 105 | $13.74 | $1,484 |
| 67028 Intravitreal Injection | Facility | 88 | 31 | $67.24 | $5,917 |
| 92250 Angiography | Facility | 71 | 68 | $14.11 | $1,002 |
| 99204 Office E&M - New | Facility | 67 | 67 | $93.54 | $6,267 |
| 92136 Ultrasound - Nonspecific | Facility | 46 | 41 | $19.98 | $919 |
| 92014 Ophthalmological E&M | Facility | 45 | 45 | $45.77 | $2,059 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 38 | 38 | $12.53 | $476 |
| 66710 Eye | Facility | 33 | 30 | $291.34 | $9,614 |
| 76514 Ultrasound - Nonspecific | Facility | 33 | 33 | $5.32 | $176 |
| 76512 Ultrasound - Nonspecific | Facility | 31 | 17 | $20.82 | $645 |
By year: 2022 $115K for 2,102 services; 2023 $131K for 2,505 services; 2024 $124K for 2,499 services.
Medicare prescription drug claims, 2024
In 2024, the drug Samuel G Alpert prescribed most often to Medicare patients was Latanoprost, with 1,651 prescriptions and refills. In total Samuel G Alpert wrote 7,317 Medicare prescriptions that cost $751K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 1,651 | 2,571 | 396 | $13K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 766 | 1,543 | 226 | $12K |
| Prednisolone Acetate Generic | 641 | 870 | 324 | $26K |
| Timolol Maleate Generic | 456 | 1,040 | 147 | $5,505 |
| Brimonidine Tartrate Generic | 416 | 741 | 129 | $12K |
| Erythromycin Erythromycin Base | 381 | 402 | 167 | $6,057 |
| Ofloxacin Generic | 338 | 361 | 221 | $3,855 |
| Dorzolamide Hcl Generic | 307 | 613 | 85 | $5,718 |
| Acetazolamide Generic | 196 | 275 | 62 | $10K |
| Lumigan Bimatoprost | 189 | 320 | 44 | $79K |
| Methazolamide Generic | 164 | 227 | 47 | $48K |
| Rhopressa Netarsudil Mesylate | 140 | 199 | 38 | $60K |
| Rocklatan Netarsudil Mesylat/Latanoprost | 126 | 193 | 32 | $68K |
| Travoprost Generic | 117 | 190 | 32 | $19K |
| Ketorolac Tromethamine Generic | 98 | 171 | 46 | $2,759 |
Brand drugs: 2,409 claims; generic drugs: 4,908 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Samuel G Alpert $40.71 ($40.71 in general payments such as food, travel and fees) from 1 company. The largest payer was New World Medical,Inc. with $40.71.
| Company | Payments | Amount |
|---|---|---|
| New World Medical,Inc. | 2 | $40.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.